The estimated Net Worth of Michael J Higgins is at least $1.51 million dollars as of 14 July 2022. Mr Higgins owns over 13,891 units of Voyager Therapeutics Inc stock worth over $196,652 and over the last 15 years he sold VYGR stock worth over $1,219,570. In addition, he makes $90,000 as Interim CEO et Pres & Chairman at Voyager Therapeutics Inc.
Mr has made over 9 trades of the Voyager Therapeutics Inc stock since 2011, according to the Form 4 filled with the SEC. Most recently he sold 13,891 units of VYGR stock worth $93,070 on 14 July 2022.
The largest trade he's ever made was exercising 258,334 units of Voyager Therapeutics Inc stock on 14 June 2013 worth over $155,000. On average, Mr trades about 14,648 units every 94 days since 2010. As of 14 July 2022 he still owns at least 31,314 units of Voyager Therapeutics Inc stock.
You can see the complete history of Mr Higgins stock trades at the bottom of the page.
Michael J. Higgins M.B.A. is the Interim CEO, Pres & Chairman at Voyager Therapeutics Inc.
As the Interim CEO et Pres & Chairman of Voyager Therapeutics Inc, the total compensation of Mr A at Voyager Therapeutics Inc is $90,000. There are 8 executives at Voyager Therapeutics Inc getting paid more, with Omar Khwaja having the highest compensation of $3,815,770.
Mr A is 59, he's been the Interim CEO et Pres & Chairman of Voyager Therapeutics Inc since . There are 9 older and 7 younger executives at Voyager Therapeutics Inc. The oldest executive at Voyager Therapeutics Inc is Dr. Steven M. Paul M.D., 70, who is the Exec. Science Advisor & Director.
Michael's mailing address filed with the SEC is C/O VOYAGER THERAPEUTICS, INC., 75 HAYDEN AVENUE, LEXINGTON, MA, 02421.
Over the last 9 years, insiders at Voyager Therapeutics Inc have traded over $22,599,571 worth of Voyager Therapeutics Inc stock and bought 9,198,716 units worth $93,782,260 . The most active insiders traders include Sanofi, Capital, Llc Eco R1 et Biosciences Inc Neurocrine. On average, Voyager Therapeutics Inc executives and independent directors trade stock every 39 days with the average trade being worth of $966,976. The most recent stock trade was executed by Robin Swartz on 2 April 2024, trading 1,357 units of VYGR stock currently worth $13,407.
voyager therapeutics is a gene therapy company developing life-changing treatments for fatal and debilitating diseases of the central nervous system (cns). voyager is committed to advancing the field of aav (adeno-associated virus) gene therapy through innovation and investment in vector optimization and engineering, dosing techniques, as well as process development and production. the company’s initial pipeline is focused on cns diseases in dire need of effective new therapies, including parkinson’s disease, a monogenic form of amyotrophic lateral sclerosis (als), and friedreich’s ataxia. founded by scientific and clinical leaders in the fields of aav gene therapy, expressed rna interference and neuroscience, voyager therapeutics was launched in 2014 with funding from leading life sciences investor third rock ventures and is headquartered in cambridge, mass. for more information, please visit www.voyagertherapeutics.com.
Voyager Therapeutics Inc executives and other stock owners filed with the SEC include: